GlassScriptPhysician profile
Ashley A Mcclure
NPI 1144093543
$1,852.30
in general payments reported to CMS, 2019-2025
21 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $47.68 · 2024: $601 · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.31 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $315.94 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $291.25 | 2024-2025 | |
| Genzyme Corporation | $230.74 | 2024-2025 | |
| Abbvie INC. | $204.76 | 2024-2025 | |
| Janssen Biotech, INC. | $167.31 | 2024-2025 | Tremfya |
| Galderma Laboratories, L.P. | $88.41 | 2025 | Nemluvio |
| Incyte Corporation | $66.19 | 2024-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $59.24 | 2025 | Libtayo |
| Sun Pharmaceutical Industries INC. | $58.34 | 2023-2024 | Odomzo, Blu-U |
| Biofrontera INC. | $52.23 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.34 | 2024-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.02 | 2025 | Cabtreo, Siliq, Jublia |
| Teva Pharmaceuticals USA, INC. | $38.67 | 2025 | |
| Lilly USA, LLC | $33.13 | 2024-2025 | Ebglyss |
| Biocon Biologics INC | $32.40 | 2025 | Yesintek |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.00 | 2025 | Sotyktu |
| Amgen INC. | $21.16 | 2024 | Otezla |
| Kyowa Kirin, INC. | $21.14 | 2024 | Poteligeo |
| Organogenesis INC. | $20.82 | 2024 | Puraply Am |
| Verrica Pharmaceuticals INC. | $16.43 | 2024 | Ycanth |
| Pfizer INC. | $14.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mcclure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.